CRVO Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -- compared to CervoMed's net margin of -10571.43%. CervoMed's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

CervoMed has a consensus price target of $20.00, signalling upside risk potential of 765.8%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 1078.24%. Given that AIM ImmunoTech has higher upside potential than CervoMed, analysts believe AIM ImmunoTech is more attractive than CervoMed.

CervoMed has a beta of 1.782, which suggesting that the stock is 78.196% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of -0.363, suggesting its less volatile than the S&P 500 by 136.26%.

CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

CervoMed quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. CervoMed's net income of -$4.8M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, CervoMed's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 23.47x versus 64.14x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -- compared to CervoMed's net margin of -31993.31%. CervoMed's return on equity of -- beat Inovio Pharmaceuticals's return on equity of -98.72%.

CervoMed has a consensus price target of $20.00, signalling upside risk potential of 765.8%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $10.67 which suggests that it could grow by 367.84%. Given that CervoMed has higher upside potential than Inovio Pharmaceuticals, analysts believe CervoMed is more attractive than Inovio Pharmaceuticals.

CervoMed has a beta of 1.782, which suggesting that the stock is 78.196% more volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 0.842, suggesting its less volatile than the S&P 500 by 15.846%.

CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

CervoMed quarterly revenues are --, which are smaller than Inovio Pharmaceuticals quarterly revenues of $100.8K. CervoMed's net income of -$4.8M is higher than Inovio Pharmaceuticals's net income of -$25.2M. Notably, CervoMed's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 23.47x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Leap Therapeutics has a net margin of -- compared to CervoMed's net margin of --. CervoMed's return on equity of -- beat Leap Therapeutics's return on equity of --.

CervoMed has a consensus price target of $20.00, signalling upside risk potential of 765.8%. On the other hand Leap Therapeutics has an analysts' consensus of $9.83 which suggests that it could grow by 182.57%. Given that CervoMed has higher upside potential than Leap Therapeutics, analysts believe CervoMed is more attractive than Leap Therapeutics.

CervoMed has a beta of 1.782, which suggesting that the stock is 78.196% more volatile than S&P 500. In comparison Leap Therapeutics has a beta of 0.168, suggesting its less volatile than the S&P 500 by 83.238%.

CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Leap Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. Leap Therapeutics pays out -- of its earnings as a dividend.

CervoMed quarterly revenues are --, which are smaller than Leap Therapeutics quarterly revenues of --. CervoMed's net income of -$4.8M is higher than Leap Therapeutics's net income of -$18.2M. Notably, CervoMed's price-to-earnings ratio is -- while Leap Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 23.47x versus 77.96x for Leap Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to CervoMed's net margin of 18.02%. CervoMed's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

CervoMed has a consensus price target of $20.00, signalling upside risk potential of 765.8%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 527.8%. Given that CervoMed has higher upside potential than Protalix BioTherapeutics, analysts believe CervoMed is more attractive than Protalix BioTherapeutics.

CervoMed has a beta of 1.782, which suggesting that the stock is 78.196% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.711, suggesting its less volatile than the S&P 500 by 28.881%.

CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

CervoMed quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. CervoMed's net income of -$4.8M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, CervoMed's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 23.47x versus 3.84x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.